Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 67% ± 14% | |
lung | 19 studies | 73% ± 20% | |
brain | 19 studies | 35% ± 18% | |
intestine | 14 studies | 69% ± 27% | |
eye | 10 studies | 64% ± 26% | |
kidney | 9 studies | 75% ± 18% | |
liver | 7 studies | 66% ± 22% | |
bone marrow | 6 studies | 59% ± 18% | |
lymph node | 6 studies | 69% ± 20% | |
pancreas | 5 studies | 81% ± 15% | |
uterus | 5 studies | 80% ± 12% | |
placenta | 4 studies | 74% ± 18% | |
prostate | 4 studies | 53% ± 10% | |
breast | 4 studies | 84% ± 8% | |
heart | 3 studies | 40% ± 16% | |
adipose | 3 studies | 43% ± 19% | |
adrenal gland | 3 studies | 72% ± 13% | |
esophagus | 3 studies | 67% ± 22% | |
skin | 3 studies | 70% ± 22% | |
stomach | 3 studies | 53% ± 25% | |
thymus | 3 studies | 77% ± 28% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 6748.32 | 245 / 245 | 100% | 459.81 | 501 / 502 |
thymus | 100% | 8711.66 | 653 / 653 | 100% | 488.99 | 602 / 605 |
liver | 100% | 9355.18 | 225 / 226 | 100% | 383.45 | 404 / 406 |
breast | 100% | 6963.36 | 459 / 459 | 99% | 381.91 | 1107 / 1118 |
intestine | 100% | 8592.38 | 966 / 966 | 99% | 397.27 | 521 / 527 |
stomach | 100% | 8271.75 | 359 / 359 | 99% | 397.65 | 282 / 286 |
kidney | 100% | 11327.19 | 89 / 89 | 99% | 349.71 | 888 / 901 |
pancreas | 99% | 5461.67 | 326 / 328 | 99% | 332.33 | 176 / 178 |
brain | 100% | 10817.12 | 2642 / 2642 | 98% | 435.07 | 692 / 705 |
lung | 100% | 9254.21 | 578 / 578 | 98% | 307.30 | 1130 / 1155 |
skin | 100% | 6336.16 | 1808 / 1809 | 98% | 444.49 | 462 / 472 |
esophagus | 100% | 6651.07 | 1441 / 1445 | 98% | 255.32 | 179 / 183 |
bladder | 100% | 8309.48 | 21 / 21 | 96% | 336.79 | 485 / 504 |
adrenal gland | 100% | 13302.59 | 258 / 258 | 96% | 523.22 | 221 / 230 |
uterus | 100% | 6497.72 | 170 / 170 | 93% | 294.68 | 429 / 459 |
ovary | 100% | 6296.38 | 180 / 180 | 77% | 187.94 | 331 / 430 |
adipose | 100% | 7394.24 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 522.52 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 557.80 | 29 / 29 |
muscle | 100% | 11411.97 | 803 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 16324.03 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 8555.92 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 281.21 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 112.66 | 1 / 1 |
blood vessel | 100% | 8432.32 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 8275.74 | 837 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0097009 | Biological process | energy homeostasis |
GO_0016567 | Biological process | protein ubiquitination |
GO_0021888 | Biological process | hypothalamus gonadotrophin-releasing hormone neuron development |
GO_0047497 | Biological process | mitochondrion transport along microtubule |
GO_1902255 | Biological process | positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator |
GO_1902527 | Biological process | positive regulation of protein monoubiquitination |
GO_0072520 | Biological process | seminiferous tubule development |
GO_0043523 | Biological process | regulation of neuron apoptotic process |
GO_0019941 | Biological process | modification-dependent protein catabolic process |
GO_0007141 | Biological process | male meiosis I |
GO_0048812 | Biological process | neuron projection morphogenesis |
GO_0051881 | Biological process | regulation of mitochondrial membrane potential |
GO_0060613 | Biological process | fat pad development |
GO_0007144 | Biological process | female meiosis I |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0008585 | Biological process | female gonad development |
GO_0061136 | Biological process | regulation of proteasomal protein catabolic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0043025 | Cellular component | neuronal cell body |
GO_0043005 | Cellular component | neuron projection |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0010008 | Cellular component | endosome membrane |
GO_0031982 | Cellular component | vesicle |
GO_0005634 | Cellular component | nucleus |
GO_0031386 | Molecular function | protein tag activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
Gene name | UBB |
Protein name | Polyubiquitin-B [Cleaved into: Ubiquitin] Epididymis secretory protein Li 50 (Ubiquitin B) Ubiquitin B |
Synonyms | hCG_1998947 HEL-S-50 |
Description | FUNCTION: [Ubiquitin]: Exists either covalently attached to another protein, or free (unanchored). When covalently bound, it is conjugated to target proteins via an isopeptide bond either as a monomer (monoubiquitin), a polymer linked via different Lys residues of the ubiquitin (polyubiquitin chains) or a linear polymer linked via the initiator Met of the ubiquitin (linear polyubiquitin chains). Polyubiquitin chains, when attached to a target protein, have different functions depending on the Lys residue of the ubiquitin that is linked: Lys-6-linked may be involved in DNA repair; Lys-11-linked is involved in ERAD (endoplasmic reticulum-associated degradation) and in cell-cycle regulation; Lys-29-linked is involved in proteotoxic stress response and cell cycle; Lys-33-linked is involved in kinase modification; Lys-48-linked is involved in protein degradation via the proteasome; Lys-63-linked is involved in endocytosis, DNA-damage responses as well as in signaling processes leading to activation of the transcription factor NF-kappa-B. Linear polymer chains formed via attachment by the initiator Met lead to cell signaling. Ubiquitin is usually conjugated to Lys residues of target proteins, however, in rare cases, conjugation to Cys or Ser residues has been observed. When polyubiquitin is free (unanchored-polyubiquitin), it also has distinct roles, such as in activation of protein kinases, and in signaling. . |
Accessions | ENST00000302182.8 ENST00000614404.1 B4DV12 J3QS39 ENST00000395839.5 ENST00000395837.1 ENST00000577640.1 ENST00000535788.1 J3QKN0 P0CG47 Q5U5U6 J3QSA3 ENST00000577958.1 ENST00000578706.5 |